Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-966 pembrolizumab plus gemcitabine/cisplatin in first-line advanced biliary tract carcinoma
NL-OMON52576Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2020
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in biliary cancer, cholangiocarcinoma (CCA) and gallbladder cancer comparing Pembrolizumab + gemcitabine + cisplatin with Placebo + gemcitabine + cisplatin (2 arms). Primary endpoint: Overall survival. Started Feb 2020; status: recruiting.
02
Drugs
03
Conditions
biliary cancercholangiocarcinoma (CCA)gallbladder cancer
Beyond the preview
Go deeper on NL-OMON52576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52576.